“Increasing Incidence of Hematopoietic Stem Cell Transplants (HSCT) ”
- This trend is primarily fueled by the growing prevalence of blood cancers, such as leukemia, lymphoma, and myeloma, which often require HSCT as a treatment option. In addition, other hematological disorders, such as aplastic anemia and certain genetic disorders, also necessitate HSCT for disease management
- As the number of patients undergoing HSCT continues to rise, so does the demand for effective GVHD treatment. GVHD is a common complication of HSCT, occurring when the transplanted donor cells attack the recipient's tissues, leading to potentially severe and life-threatening symptoms. Therefore, the increasing incidence of HSCT directly translates to a higher need for GVHD treatment to manage and mitigate the effects of this complication
For instance,
- In October 2023, as per an article published by Frontiers Media S.A., the number of transplantations is steadily increasing globally, with nearly 20,000 allo-HCT transplants reported by the European Society for Blood and Marrow Transplantation (EBMT) in 2019 and over 9,000 transplants in the United States during the same period, as per the Center for International Blood and Marrow Transplant Research (CIBMTR)
